New

Global ETF Survey Is Live! 600+ ETF Professionals Weigh In. See Results →

Advertisement
Advertisement

PBEvsIBBETF Comparison

ETF 1
PBE

Invesco Dynamic Biotechnology & Genome ETF

This fund is part of
BioTech & Genomics
+5.19%
VS
ETF 2
IBB

iShares Biotechnology ETF

This fund is part of
US Health Care
+0.62%

Invesco Dynamic Biotechnology & Genome ETF (PBE) belongs to the BioTech & Genomics segment. iShares Biotechnology ETF (IBB) is part of the US Health Care segment. PBE's top 1 sector exposures are Healthcare. In contrast, IBB's top sector exposures are Healthcare, Non-Corporate and Non-Energy Materials. PBE is more expensive with a Total Expense Ratio (TER) of 0.59%, versus 0.44% for IBB. PBE is up 25.32% year-to-date (YTD) with +$109M in YTD flows. IBB performs better with 28.25% YTD performance, and +$614M in YTD flows. Run a side-by-side ETF comparison of PBE and IBB below, and assess how they stack up in performance, liquidity, risk, exposure, holdings, and more, helping you select the best ETF for your investments.

Find out how industry players manage ETF portfolios.  Discover our library of Model portfolios

PBE vs IBB performance and flow charts

Performance

-6.0-4.0-2.00.02.04.0%Sep 28Oct 5Oct 12Oct 19Oct 26

Cumulative Flows

0 M100 M200 M300 M400 M500 MSep 28Oct 5Oct 12Oct 19Oct 26

Get all the metrics on this page, and more, through a reliable ETF data feed

Daily, global ETF data for advanced analysis or integration into apps (API), from our partner Trackinsight.

Historic performance and flows
Data as of 10/28/2026
1M3MYTD1Y3Y5Y
Perf.
PBE
IBB
+4.58%+2.64%
+11.06%+13.54%
+25.32%+28.25%
+39.95%+37.47%
+96.33%+92.71%
+37.20%+36.70%
Flows
PBE
IBB
-$5M+$296M
+$106M+$516M
+$109M+$614M
+$111M+$1.83B
+$58M-$30M
+$61M-$947M
Volatility and drawdown
3M1Y3Y5Y
Volatility
PBE
IBB
+21.27%+26.30%
+20.03%+22.73%
+20.60%+21.41%
+22.67%+22.59%
Max drawdown
PBE
IBB
-5.97%-7.78%
-11.70%-9.61%
-22.21%-24.82%
-32.63%-35.62%
Max drawdown duration
PBE
IBB
46d70d
166d151d
324d377d
1468d1468d
Trading data

Create an account to view trading data

Join for free
PBE
IBB
Last sale
10/28/2026 at 1:30 PM
$101.87
$216.35
Previous close
10/28/2026
$100.74
$212.20
Consolidated volume
10/28/2026
Average volume
30 days
Average discount or premium
30 days
Average Bid/Ask spread
30 days
Replication quality
Data as of September 30, 2026
1-year trailing difference

Create an account to view replication metrics

Join for free

Create an account to view replication quality

Join for free
PBE
IBB
Tracking error
Tracking difference
1 year cumulative return difference
Best
Worst
Daily return difference
Average
Worst
Advertisement
Main metrics
Last update 10/28/2026 at 1:30 PM
Live
Closed
PBE
IBB
Last price
$101.87
$216.35
1D performance
+1.12%
+1.96%
AuM$438.68 M$11.27 B
E/R0.59%0.44%
Characteristics
PBE
IBB
Management strategyPassivePassive
ProviderInvescoiShares
BenchmarkDynamic Biotech & Genome Intellidex IndexNYSE Biotechnology Index
N° of holdings30241
Asset classEquitiesEquities
Trailing 12m distribution yield
Join
Join
Inception dateJune 23, 2005February 5, 2001
ESGNoNo
Advertisement
Exposure

Countries

PBE
USA
97.22%
Other
2.78%
IBB
USA
86.02%
Other
13.98%

Sectors

PBE
Healthcare
100%
Other
0%
IBB
Healthcare
99.9%
Other
0.1%
Advertisement

Diversification

PBE

Total weight of top 15 holdings out of 15

63.67%
IBB

Total weight of top 15 holdings out of 15

56.64%

Top 15 holdings

Data as of August 31, 2026
PBE
CareDx, Inc.
5.49%
Amgen, Inc.
5.38%
Regeneron Pharmaceuticals, Inc.
5.26%
Vertex Pharmaceuticals, Inc.
5.21%
Royalty Pharma Plc
4.76%
Biogen, Inc.
4.75%
Gilead Sciences, Inc.
4.61%
United Therapeutics Corp.
3.77%
Omeros Corp.
3.73%
Repligen Corp.
3.57%
Illumina, Inc.
3.54%
Halozyme Therapeutics, Inc.
3.51%
Bio-Techne Corp.
3.41%
Protagonist Therapeutics, Inc.
3.37%
Alnylam Pharmaceuticals, Inc.
3.31%
IBB
Amgen, Inc.
8.45%
Vertex Pharmaceuticals, Inc.
8.05%
Gilead Sciences, Inc.
7.21%
Regeneron Pharmaceuticals, Inc.
5.72%
argenx SE
3.80%
Moderna, Inc.
3.62%
Natera, Inc.
3.12%
Revolution Medicines, Inc.
2.78%
Illumina, Inc.
2.29%
Alnylam Pharmaceuticals, Inc.
2.27%
Biogen, Inc.
2.25%
BeOne Medicines Ltd.
2.03%
Insmed, Inc.
1.85%
Incyte Corp.
1.73%
United Therapeutics Corp.
1.49%
Frequently asked questions about PBE and IBB

How have the PBE and IBB ETFs performed in 2026?

As of October 28, 2026, PBE is up 25.32% year-to-date (YTD), while IBB has returned 28.25%. That puts IBB better performer ahead so far this year.

Which ETF is attracting more investor money: PBE or IBB?

Year-to-date, the PBE ETF saw +$109M in flows, compared to +$614M for IBB.

Which ETF is more volatile: PBE or IBB?

Over the past year, PBE had a volatility of 20.03%, while IBB experienced 22.73%.

Which ETF is bigger: PBE or IBB?

As of October 28, 2026, PBE holds $438.68 M in assets under management (AUM), while IBB manages $11.27 B.

What sectors do the PBE and IBB ETFs invest in?

PBE leans toward sectors like Healthcare. Meanwhile, IBB focuses on Healthcare.

What are the top holdings of the PBE ETF and IBB ETF?

PBE top holdings include CareDx, Inc., Amgen, Inc. and Regeneron Pharmaceuticals, Inc.. IBB holds in its top three: Amgen, Inc., Vertex Pharmaceuticals, Inc. and Gilead Sciences, Inc..

Which ETF is more diversified: PBE or IBB?

PBE holds 30 securities with 63.67% of its assets in the top 15. IBB has 241 securities and a top 15 weight of 56.64%.

Advertisement
Advertisement
Advertisement
New Report

ETFs’ Next Act: From Access to Selection

Global ETF Survey 2026